期刊文献+

肺组织中不同巨噬细胞的生理和病理研究进展

Advances on physiology and pathology of subpopulations of macrophages in the lung tissue
下载PDF
导出
摘要 肺组织中的巨噬细胞调控免疫反应对于维持肺部组织稳态至关重要,根据其不同的来源和肺解剖部位分为肺泡巨噬细胞、间质巨噬细胞、血管周围巨噬细胞和炎性巨噬细胞等。肺泡巨噬细胞分布在肺泡腔内,主要负责维持肺泡表面活性物质稳态、抵御病原微生物和调节免疫反应;间质巨噬细胞在肺组织中发挥维持稳态、调节免疫和抗炎的功能;血管周围巨噬细胞具有抗原提呈、免疫调节作用,在抑制肺部炎症、改善肺纤维化以及调控肺肿瘤进展中起着重要作用;炎性巨噬细胞在炎症时由单核细胞分化而来并调控炎症的进程。本文主要讨论了肺组织中不同巨噬细胞的来源以及生理和病理状态下的功能,以探讨可能的治疗靶点。 Macrophages are vital in maintaining tissue homeostasis in the lungs by modulating and regulating immune responses.Based on different origins and anatomical locations,macrophages in the lungs are categorized into alveolar macrophages,interstitial macrophages,perivascular macrophages,and inflammatory macrophages.Alveolar macrophages are located in the alveolar spaces and are primarily responsible for maintaining alveolar surfactant homeostasis,defending against pathogens and regulating immune responses.Interstitial macrophages can maintain homeostasis,regulate immunity and anti-inflammation in the lung tissue.Perivascular macrophages play a crucial role in inhibiting lung inflammation,improving pulmonary fibrosis,and regulating lung tumor progression due to antigen-presenting and immunomodulatory effects.Inflammatory macrophages,which are differentiated from monocytes during inflammation,regulate the inflammatory process.This article reviews the origins of various subpopulations of macrophages in the lung tissue and their physiological and pathological functions as well as discusses the underlying mechanisms and potential therapeutic targets.
作者 钟晓辉 吕成杰 赖登明 舒强 ZHONG Xiaohui;LYU Chengjie;LAI Dengming;SHU Qiang(Department of Thoracic and Cardiovascular Surgery,Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,National Regional Medical Center for Children,Hangzhou 310052,China;Department of Neonatal Surgery,Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,National Regional Medical Center for Children,Hangzhou 310052,China;Children’s Health Innovation Research Center,Binjiang Institute of Zhejiang University,Hangzhou 310053,China)
出处 《浙江大学学报(医学版)》 CAS CSCD 北大核心 2024年第5期650-658,共9页 Journal of Zhejiang University(Medical Sciences)
基金 国家自然科学基金(82272191)。
关键词 巨噬细胞 肺组织 生理 病理 炎症 免疫 综述 Macrophage Lung tissue Physiological Pathological Inflammation Immune Review
  • 相关文献

参考文献2

二级参考文献82

  • 1Buck E, Eyzaguirre A, Brown E, et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5:2676-84.
  • 2Di Cosimo S, Matar P, Rojo F, et al. The mTOR pathway inhibitor RAD001 induces activation of AKT which is completely abolished by gefitinib, an anti- EGFR tyrosine kinase inhibitorj and combined sequence specific treatment results in greater antitumor activity. Proc Am Assoc Cancer Res 2004; 45:1233.
  • 3Di Cosimo S, Matar P, Rojo F, et al. Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (roTOR) inhibitor everolimus (RAD001). J Clin Oncol 2004, 22 (suppl):213s (abstract 3074).
  • 4Morgillo F, Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat 2005; 8:298-310.
  • 5Farace F, Massard C, Borghi E, et al. Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor ceils. Ann Oncol 2007; 18:1421-2.
  • 6O'Hanlon LH. Taking down tumors: vascular disrupting agents entering clinical trials. J Natl Cancer Inst 2005; 97:1244-5.
  • 7O'Reilly KE, Rojo F, She Q B, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8.
  • 8Herbst RS, Johnson DH, Mininberg E, et al. Phase Ⅰ/Ⅱ trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.J Clin Onco12005; 23:2544-55.
  • 9Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase Ⅱ study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-celllung cancer.J Clin Onco12007; 2S:4743-S0.
  • 10Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in nonsmall celllung cancer. Oncologist 2008; 13:139-47.

共引文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部